Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Saphnelo Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0202

    Saphnelo (anifrolumab-fnia) for systemic lupus erythematosus

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0202 alerts

    Get alerted when Policy CC-0202 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization for Saphnelo in adults with moderate-to-severe active systemic lupus erythematosus (SLE). It establishes initial and continuation criteria, non-approval conditions, approval durations, quantity limits, and applicable billing codes.

    Policy Summary
    PayerEmpire Bluecross
    PolicySaphnelo (anifrolumab-fnia) for systemic lupus erythematosus
    Policy CodePolicy CC-0202
    Change TypeAnnual review — modified
    Effective DateSeptember 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming SLE diagnosis, positive serology, active moderate-to-severe disease, and at least 30 days of standard therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual review removed the SLEDAI score requirement and specific anti-dsDNA thresholds from the Saphnelo criteria.

    The 2026 annual review removed continuation criteria addressing active central nervous system lupus and lupus nephritis and consolidated these conditions into non-approval criteria.

    The policy added quantity limits for the 120 mg/0.8 mL Saphnelo prefilled syringe or autoinjector.

    The policy removed the prior restriction against use with cyclophosphamide.

    The policy removed the SLEDAI score requirement and specific anti-dsDNA thresholds from the clinical criteria.

    The policy removed continuation criteria addressing active central nervous system lupus and lupus nephritis.

    The policy removed selected non-approvable criteria.

    The policy added the Saphnelo prefilled syringe and autoinjector dosage forms to the quantity limits.

    The policy previously removed the restriction against using Saphnelo with cyclophosphamide.

    The policy history records clarification of diagnosis requirements for systemic lupus erythematosus.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+Minimum age for initial therapy
    30 daysRequired standard therapy before initial approval
    6 monthsInitial approval duration
    1 yearContinuation approval duration
    1/28 daysQuantity limit: 300 mg vial
    4/28 daysQuantity limit: 120 mg syringe/autoinjector

    Coverage Criteria

    Initial Therapy

    Initial requests may be approved if all of the following criteria are met.

    • Eligibility and diagnosis: The individual is 18 years of age or older, has a diagnosis of systemic lupus erythematosus per the American College of Rheumatology, and has moderate-to-severe active disease while on the current SLE treatment regimen.Age >= 18
    • Serologic verification: The diagnosis is verified by a history of a positive antinuclear antibody (ANA) titer or positive anti-dsDNA based on the laboratory reference range.ANA >= 1:80 or positive anti-dsDNA based on laboratory reference range
    • Failure of standard therapy: SLE remains active while the individual has received corticosteroids, antimalarials, or immunosuppressants, alone or in combination, for at least the last 30 days.At least 30 days
    • Concurrent standard therapy: Saphnelo is used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants.

      Other biologics and cyclophosphamide are not included as standard therapy for this criterion.

    Continuation Therapy

    Continuation requests may be approved if all of the following criteria are met.

    • Therapeutic response: Documentation shows improvement in disease activity following treatment with Saphnelo, indicating a therapeutic response.
    • Concurrent standard therapy: Saphnelo continues to be used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants.

      Other biologics are not included as standard therapy for this criterion.

    Not Approved

    Saphnelo may not be approved if any of the following conditions are present.

    Non-Approval Conditions

    • Severe active CNS lupus: The individual has evidence of severe active central nervous system lupus, such as psychosis or seizures.
    • Severe active lupus nephritis: The individual has evidence of severe active lupus nephritis.Proteinuria > 6 g/day, serum creatinine > 2.5 mg/dL, or requiring dialysis
    • Prohibited concomitant therapy: The individual is using Saphnelo with another biologic, including B-cell-targeted therapies or belimumab, or with voclosporin.

    Coverage is available with criteria for initial and continuation therapy. Initial requests require an individual to be 18 years or older with moderate-to-severe active systemic lupus erythematosus diagnosed according to American College of Rheumatology criteria, supported by a positive ANA titer of at least 1:80 or positive anti-dsDNA based on the laboratory reference range. Disease must remain active despite corticosteroids, antimalarials, or immunosuppressants used alone or in combination for at least 30 days, and Saphnelo must be used with standard therapy.

    Saphnelo may not be approved when severe active central nervous system lupus, such as psychosis or seizures, is present; when severe active lupus nephritis is present, including proteinuria greater than 6 g/day, serum creatinine greater than 2.5 mg/dL, or a need for dialysis; or when Saphnelo is used with another biologic, including B-cell-targeted therapies or belimumab, or with voclosporin.

    Coding and Clinical Thresholds

    ICD-10 DiagnosisICD-10
    M32.0-M32.9Systemic lupus erythematosus (SLE)
    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Saphnelo (anifrolumab-fnia) subcutaneous (SC)]
    J0491Injection, anifrolumab-fnia, 1 mg [Saphnelo intravenous (IV)]
    J3590Unclassified biologics [when specified as Saphnelo (anifrolumab-fnia) subcutaneous (SC)]
    HCPCS codes referenced in coding historyHCPCS
    J0491HCPCS code for Saphnelo; description was updated in the coding history
    C9399HCPCS NOC code for Saphnelo subcutaneous
    J3590HCPCS NOC code for Saphnelo subcutaneous
    Previously added and subsequently removed HCPCS codesHCPCS
    J3490HCPCS code added in prior coding history; later removed
    C9086HCPCS code added in prior coding history; later removed
    ICD-10-CM diagnosis codesICD-10
    M32.0-M32.9ICD-10-CM systemic lupus erythematosus code range
    ANA Titer Threshold
    Required ANA titerGreater than or equal to 1:80
    Alternative serologic verificationPositive anti-dsDNA based on the laboratory reference range
    Applies toInitial Saphnelo requests for systemic lupus erythematosus
    Severe Active Lupus Nephritis: Proteinuria
    Proteinuria thresholdGreater than 6 g/day
    ConditionSevere active lupus nephritis

    Provider Documentation and Action Items

    Prior Authorization

    Obtain prior authorization

    Prior authorization applies to initial and continuation requests for Saphnelo reviewed under the medical benefit. Initial approval requires all initial clinical criteria; continuation approval requires documented therapeutic response and ongoing combination with standard therapy.

    Documentation Required

    Document SLE diagnosis and serology

    Submit documentation confirming a systemic lupus erythematosus diagnosis under American College of Rheumatology criteria and a history of positive serology: an ANA titer greater than or equal to 1:80 or positive anti-dsDNA based on the laboratory reference range.

    Documentation Required

    Document active disease and treatment history

    Therapy Background

    Saphnelo (anifrolumab-fnia) is an intravenously administered type I interferon receptor antagonist and biologic immunomodulator. It is used as add-on treatment for adults with moderate-to-severe active systemic lupus erythematosus (SLE) whose disease remains active despite standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants.

    The policy does not support use in severe active lupus nephritis or severe active central nervous system lupus, including presentations such as psychosis or seizures.

    Clinical Definitions

    Antinuclear Antibody (ANA) Titer
    DefinitionMeasures the concentration of antinuclear autoantibodies in the blood
    Typically normal or negativeLess than 1:40
    Low positive1:40; considered common in healthy individuals
    Low positive with possible significance1:80; could be significant depending on other signs and symptoms
    Moderate positive1:160
    High or very high positive1:320 is high positive; greater than 1:320 is very high positive

    Initial Therapy Criteria

    Initial Therapy

    Initial requests may be approved when all of the following criteria are met.

    Initial Therapy: The individual is at least 18 years old; has systemic lupus erythematosus diagnosed per American College of Rheumatology criteria; has moderate-to-severe active disease; has a documented ANA titer of at least 1:80 or positive anti-dsDNA based on the laboratory reference range; has remained active despite corticosteroids, antimalarials, or immunosuppressants, alone or in combination, for at least 30 days; and will use Saphnelo with standard therapy.Age >= 18; ANA >= 1:80 or positive anti-dsDNA; standard therapy for at least 30 days

    Standard therapy may include corticosteroids, antimalarials, and/or immunosuppressants. Other biologics and cyclophosphamide are not included as standard therapy for this criterion.

    Continuation Criteria

    Continuation Therapy

    Continuation requests may be approved when all of the following criteria are met.

    • Therapeutic response: Documentation shows improvement in disease activity following treatment with Saphnelo, indicating a therapeutic response.
    • Concurrent standard therapy: The individual continues to use Saphnelo in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants.

      Other biologics are not included as standard therapy for this criterion.

    Quantity Limits

    Saphnelo 300 mg/2 mL Vial
    ProductSaphnelo (anifrolumab-fnia) 300 mg/2 mL vial
    Quantity limit1 vial
    Limit periodPer 28 days
    Saphnelo 120 mg/0.8 mL Syringe or Autoinjector
    ProductSaphnelo (anifrolumab-fnia) 120 mg/0.8 mL syringe or autoinjector
    Quantity limit4 syringes or autoinjectors
    Limit periodPer 28 days
    Policy Summary
    PayerEmpire Bluecross
    PolicySaphnelo (anifrolumab-fnia) for systemic lupus erythematosus
    Policy CodePolicy CC-0202
    Change TypeAnnual review — modified
    Effective DateSeptember 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming SLE diagnosis, positive serology, active moderate-to-severe disease, and at least 30 days of standard therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Action ItemsTherapy BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity Limits
    Coverage implicationSaphnelo may not be approved when this threshold is met
    Severe Active Lupus Nephritis: Serum Creatinine
    Serum creatinine thresholdGreater than 2.5 mg/dL
    ConditionSevere active lupus nephritis
    Coverage implicationSaphnelo may not be approved when this threshold is met
    Standard Therapy Before Initial Request
    Minimum durationAt least the last 30 days
    Required treatmentCorticosteroids, antimalarials, or immunosuppressants, alone or in combination
    Required disease statusSLE remains active while on the current treatment regimen

    Document that SLE is moderate to severe and active on the current treatment regimen. Show that disease remains active despite corticosteroids, antimalarials, or immunosuppressants, used alone or in combination, for at least the last 30 days.

    Documentation Required

    Confirm concurrent standard therapy

    Document that Saphnelo will be used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants. Other biologics and cyclophosphamide are not included as standard therapy for the initial-treatment criterion.

    Documentation Required

    Show response for continuation

    For continuation requests, provide documentation showing improvement in disease activity following Saphnelo treatment, indicating a therapeutic response, and confirm that Saphnelo continues to be used with standard therapy.

    Denial Risk

    Screen for severe active CNS lupus

    Approval may be denied when there is evidence of severe active central nervous system lupus. Examples include psychosis or seizures.

    • Psychosis
    • Seizures
    Denial Risk

    Screen for severe active lupus nephritis

    Approval may be denied for severe active lupus nephritis. The policy defines this as proteinuria greater than 6 g/day, serum creatinine greater than 2.5 mg/dL, or a need for dialysis.

    • Proteinuria > 6 g/day
    • Serum creatinine > 2.5 mg/dL
    • Requires dialysis
    Denial Risk

    Avoid prohibited combination therapy

    Approval may be denied when Saphnelo is used with another biologic, including B-cell-targeted therapies or belimumab, or when it is used with voclosporin.

    • Another biologic
    • B-cell-targeted therapies or belimumab
    • Voclosporin
    Saphnelo Quantity-Limit Dosage Forms
    Policy changePrefilled syringe and autoinjector dosage forms were added to the quantity limits
    Added dosage formPrefilled syringe
    Added dosage formAutoinjector